Cargando…

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

BACKGROUND: Amyloid pathology, which is one of the characteristics of Alzheimer’s disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1–42 is evident in AD, and the CSF ratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehmann, Sylvain, Dumurgier, Julien, Ayrignac, Xavier, Marelli, Cecilia, Alcolea, Daniel, Ormaechea, Juan Fortea, Thouvenot, Eric, Delaby, Constance, Hirtz, Christophe, Vialaret, Jérôme, Ginestet, Nelly, Bouaziz-Amar, Elodie, Laplanche, Jean-Louis, Labauge, Pierre, Paquet, Claire, Lleo, Alberto, Gabelle, Audrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532565/ https://www.ncbi.nlm.nih.gov/pubmed/33008460 http://dx.doi.org/10.1186/s13195-020-00696-1

Ejemplares similares

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM(R) Scale
por: Lehmann, Sylvain, et al.
Publicado: (2018)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid
por: Hirtz, Christophe, et al.
Publicado: (2016)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

The alternative proteome in neurobiology
por: Mohaupt, Pablo, et al.
Publicado: (2022)

β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer’s disease
por: Mohaupt, Pablo, et al.
Publicado: (2022)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
por: Lehmann, Sylvain, et al.
Publicado: (2014)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
por: Perea, Juan R., et al.
Publicado: (2018)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry
por: Bros, Pauline, et al.
Publicado: (2015)

Hepcidin and ferritin levels in restless legs syndrome: a case–control study
por: Chenini, Sofiene, et al.
Publicado: (2020)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Hospitalization Risks for Neurological Disorders in Primary Sjögren’s Syndrome Patients
por: Goulabchand, Radjiv, et al.
Publicado: (2022)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches
por: Vialaret, Jerome, et al.
Publicado: (2018)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
por: Delaby, Constance, et al.
Publicado: (2021)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders
por: Delaby, C., et al.
Publicado: (2020)

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study
por: Vrillon, Agathe, et al.
Publicado: (2022)

Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
por: Mohaupt, Pablo, et al.
Publicado: (2023)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis
por: Lebrun, Christine, et al.
Publicado: (2017)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
por: Hirtz, Christophe, et al.
Publicado: (2023)

Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer’s disease
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2016)

Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice
por: Trueba-Sáiz, A, et al.
Publicado: (2013)

The cognitive aftermath of COVID-19
por: Lleó, Alberto, et al.
Publicado: (2020)

Proteomics Challenges for the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson’s Disease
por: Pons, Marie-Laure, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oj4v162bc6l1r7dgt3i8jld13d